Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.

Sylla M, Dolo O, Maiga AI, Traore FT, Coulibaly YA, Togo J, Fofana DB, Dicko-Traore F, Doumbia S, Orsega S, Diallo S, Murphy RL, Calvez V, Marcelin AG.

Arch Pediatr. 2019 Jul 12. pii: S0929-693X(19)30105-8. doi: 10.1016/j.arcped.2019.06.002. [Epub ahead of print]

PMID:
31307909
2.

Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya.

Mbae M, Owen L, Elisha KK, Ndhere A, Mugambi NS, Yogev R, Murphy RL, Jarvis JN.

AIDS. 2019 Jul 1;33(8):1404-1406. doi: 10.1097/QAD.0000000000002216. No abstract available.

PMID:
31157666
3.

Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali.

Baya B, Achenbach CJ, Kone B, Toloba Y, Dabitao DK, Diarra B, Goita D, Diabaté S, Maiga M, Soumare D, Ouattara K, Kanoute T, Berthe G, Kamia YM, Sarro YDS, Sanogo M, Togo ACG, Dembele BPP, Coulibaly N, Kone A, Akanbi M, Belson M, Dao S, Orsega S, Siddiqui S, Doumbia S, Murphy RL, Diallo S.

Int J Infect Dis. 2019 Apr;81:149-155. doi: 10.1016/j.ijid.2019.02.004. Epub 2019 Feb 14.

4.

Comparing Treatment Outcomes of Antiretroviral Therapy in HIV-1 and HIV-2 Infected Patients, in Bamako, Mali.

Oumar AA, Cissoko Y, Konaté I, Kane A, Dembélé JP, Cissé M, Murphy RL, Yombi JC, Seydi M, Dao S, Maiga M.

Curr Find Infect Dis. 2018;2018(1). pii: RD-INF-10003. Epub 2018 Nov 26.

5.

Simultaneous diagnosis of tuberculous and non-tuberculous mycobacterial diseases: Time for a better patient management.

Sarro YD, Kone B, Diarra B, Kumar A, Kodio O, Fofana DB, Achenbach CJ, Beavogui AH, Seydi M, Holl JL, Taiwo B, Diallo S, Doumbia S, Murphy RL, McFall SM, Maiga M.

Clin Microbiol Infect Dis. 2018 Dec;3(3). doi: 10.15761/CMID.1000144. Epub 2018 Nov 30.

6.

Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali.

Diarra B, Kone M, Togo ACG, Sarro YDS, Cisse AB, Somboro A, Degoga B, Tolofoudie M, Kone B, Sanogo M, Baya B, Kodio O, Maiga M, Belson M, Orsega S, Krit M, Dao S, Maiga II, Murphy RL, Rigouts L, Doumbia S, Diallo S, de Jong BC.

PLoS One. 2018 Dec 12;13(12):e0208603. doi: 10.1371/journal.pone.0208603. eCollection 2018.

7.

Differential HLA allele frequency in Mycobacterium africanum vs Mycobacterium tuberculosis in Mali.

Kone A, Diarra B, Cohen K, Diabate S, Kone B, Diakite MT, Diarra H, Sanogo M, Togo ACG, Sarro YDS, Baya B, Coulibaly N, Kodio O, Achenbach CJ, Murphy RL, Holl JL, Siddiqui S, Doumbia S, Bishai WR, Diallo S, Maiga M.

HLA. 2019 Jan;93(1):24-31. doi: 10.1111/tan.13448. Epub 2019 Jan 2.

PMID:
30516034
8.

Association between patient-reported HIV status and provider recommendation for screening in an opportunistic cervical Cancer screening setting in Jos, Nigeria.

Musa J, Achenbach CJ, Evans CT, Jordan N, Daru PH, Hou L, Murphy RL, Adewole IF, Simon MA.

BMC Health Serv Res. 2018 Nov 22;18(1):885. doi: 10.1186/s12913-018-3700-y.

9.

Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.

Oumar AA, Bagayoko-Maiga K, Bahachimi A, Maiga M, Cere MC, Diarra Z, Chatelut E, Sylla M, Murphy RL, Dao S, Gandia P.

J Pharmacol Exp Ther. 2018 Sep;366(3):479-484. doi: 10.1124/jpet.118.249938. Epub 2018 Jul 9.

PMID:
29986950
10.

Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG; VHICS Study Team.

Open Forum Infect Dis. 2018 Jun 4;5(6):ofy103. doi: 10.1093/ofid/ofy103. eCollection 2018 Jun.

11.

Promoter methylation of PGC1A and PGC1B predicts cancer incidence in a veteran cohort.

Kresovich JK, Joyce BT, Gao T, Zheng Y, Zhang Z, Achenbach CJ, Murphy RL, Just AC, Shen J, Yang H, Vokonas P, Schwartz J, Baccarelli AA, Hou L.

Epigenomics. 2018 Jun;10(6):733-743. doi: 10.2217/epi-2017-0141. Epub 2018 Jun 11.

12.

Are large clinical trials in orthopaedic trauma justified?

Sprague S, Tornetta P 3rd, Slobogean GP, O'Hara NN, McKay P, Petrisor B, Jeray KJ, Schemitsch EH, Sanders D, Bhandari M; FLOW Investigators.

BMC Musculoskelet Disord. 2018 Apr 20;19(1):124. doi: 10.1186/s12891-018-2029-3.

13.

Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures.

Sprague S, Bhandari M, Heetveld MJ, Liew S, Scott T, Bzovsky S, Heels-Ansdell D, Zhou Q, Swiontkowski M, Schemitsch EH; FAITH Investigators.

Bone Joint J. 2018 Mar 1;100-B(3):361-369. doi: 10.1302/0301-620X.100B3.BJJ-2017-0853.R1.

PMID:
29589490
14.

Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults.

Kone B, Maiga M, Baya B, Sarro Y, Coulibaly N, Kone A, Diarra B, Sanogo M, Togo A, Goita D, Dembele M, Polis MA, Warfield J, Belson M, Dao S, Orsega S, Murphy RL, Diallo S, Siddiqui S.

J Blood Lymph. 2017;7(1). pii: 154. doi: 10.4172/2165-7831.1000154. Epub 2017 Mar 15.

15.

Clinical characteristics of non-tuberculous mycobacterial pulmonary infections in Bamako, Mali.

Kone B, Sarro YS, Maiga M, Sanogo M, Somboro AM, Diarra B, Togo ACG, Coulibaly N, Dembele BPP, Goita D, Baya B, Kone A, Diabaté S, Polis MA, Belson M, Dao S, Orsega S, Achenbach CJ, Murphy RL, Diallo S, Siddiqui S.

Epidemiol Infect. 2018 Feb;146(3):354-358. doi: 10.1017/S0950268817003090. Epub 2018 Jan 15.

16.

Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.

Silas OA, Achenbach CJ, Murphy RL, Hou L, Sagay SA, Banwat E, Adoga AA, Musa J, French DD.

Expert Rev Vaccines. 2018 Jan;17(1):91-98. doi: 10.1080/14760584.2018.1411195. Epub 2017 Dec 6. Review.

PMID:
29183182
17.

The most frequent Mycobacterium tuberculosis complex families in mali (2006-2016) based on spoligotyping.

Togo ACG, Kodio O, Diarra B, Sanogo M, Coulibaly G, Bane S, Diallo F, Somboro AM, Cisse AB, Baya B, Goita D, Diabate S, Kone B, Sarro YDS, Maiga M, Toloba Y, Belson M, Orsega S, Dao S, Murphy RL, Siddiqui S, Doumbia S, Diallo S.

Int J Mycobacteriol. 2017 Oct-Dec;6(4):379-386. doi: 10.4103/ijmy.ijmy_140_17.

18.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

19.

Extensively drug resistant tuberculosis in Mali: a case report.

Diarra B, Toloba Y, Konate B, Sanogo M, Togo ACG, Camara F, Berthe G, Soumaré D, Baya B, Goita D, Sarro YDS, Maiga M, Belson M, Orsega S, Dao S, Murphy RL, Siddiqui S, de Jong BC, Doumbia S, Diallo S.

BMC Res Notes. 2017 Nov 6;10(1):561. doi: 10.1186/s13104-017-2890-4.

20.

Vitamin D Use and Health Outcomes After Surgery for Hip Fracture.

Sprague S, Slobogean GP, Bogoch E, Petrisor B, Garibaldi A, O'Hara N, Bhandari M; FAITH Investigators.

Orthopedics. 2017 Oct 1;40(5):e868-e875. doi: 10.3928/01477447-20170907-01.

PMID:
29039872
21.

Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program.

Meloni ST, Chaplin B, Idoko J, Agbaji O, Akanmu S, Imade G, Okonkwo P, Murphy RL, Kanki PJ.

AIDS Res Ther. 2017 Oct 13;14(1):58. doi: 10.1186/s12981-017-0184-5.

22.

Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis.

Musa J, Achenbach CJ, O'Dwyer LC, Evans CT, McHugh M, Hou L, Simon MA, Murphy RL, Jordan N.

PLoS One. 2017 Sep 5;12(9):e0183924. doi: 10.1371/journal.pone.0183924. eCollection 2017. Review. Erratum in: PLoS One. 2017 Dec 29;12 (12 ):e0190661.

23.

Erratum to: Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.

Silas OA, Achenbach CJ, Hou L, Murphy RL, Egesie JO, Sagay SA, Agbaji OO, Agaba PA, Musa J, Manasseh AN, Jatau ED, Dauda AM, Akanbi MO, Mandong BM.

Infect Agent Cancer. 2017 Jun 26;12:37. doi: 10.1186/s13027-017-0149-2. eCollection 2017.

24.

Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.

Silas OA, Achenbach CJ, Hou L, Murphy RL, Egesie JO, Sagay SA, Agbaji OO, Agaba PE, Musa J, Manasseh AN, Jatau ED, Dauda AM, Akanbi MO, Mandong BM.

Infect Agent Cancer. 2017 Jun 5;12:34. doi: 10.1186/s13027-017-0144-7. eCollection 2017. Erratum in: Infect Agent Cancer. 2017 Jun 26;12 :37.

25.

Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study.

Akanbi MO, Achenbach C, Taiwo B, Idoko J, Ani A, Isa Y, Agbaji O, Ukoli C, Akande P, Maiga M, Murphy RL.

BMC Pulm Med. 2017 May 30;17(1):87. doi: 10.1186/s12890-017-0430-6.

26.

Individualized antiretroviral therapeutic approaches: less can be more.

Katlama C, Ghosn J, Murphy RL.

AIDS. 2017 May 15;31(8):1065-1071. doi: 10.1097/QAD.0000000000001476. No abstract available.

PMID:
28358730
27.

High Rates of Baseline Drug Resistance and Virologic Failure Among ART-naive HIV-infected Children in Mali.

Crowell CS, Maiga AI, Sylla M, Taiwo B, Kone N, Oron AP, Murphy RL, Marcelin AG, Traore B, Fofana DB, Peytavin G, Chadwick EG.

Pediatr Infect Dis J. 2017 Nov;36(11):e258-e263. doi: 10.1097/INF.0000000000001575.

28.

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.

Sanogo M, Kone B, Diarra B, Maiga M, Baya B, Somboro AM, Sarro YS, Togo ACG, Dembele BPP, Goita D, Kone A, M'Baye O, Coulibaly N, Diabate S, Traore B, Diallo MH, Coulibaly YI, Saleeb P, Belson M, Orsega S, Siddiqui S, Polis MA, Dao S, Murphy RL, Diallo S.

Clin Microbiol Infect. 2017 Jun;23(6):408.e1-408.e6. doi: 10.1016/j.cmi.2017.01.004. Epub 2017 Jan 18.

29.

Screening new tuberculosis patients in Mali for rifampicin resistance at 2months.

Diarra B, Cissé AB, Kodio O, Sanogo M, Baya B, Togo AC, Somboro A, Tolofoudié M, Degoga B, Keita ML, Diallo F, Nguiakam N, Coulibaly G, Bane S, Sarro YD, Doumbia S, Murphy RL, Diallo S, Dejong BC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S42-S43. doi: 10.1016/j.ijmyco.2016.09.052. Epub 2016 Nov 11.

30.

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.

Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

J Antimicrob Chemother. 2017 Mar 1;72(3):820-828. doi: 10.1093/jac/dkw458.

PMID:
27999038
31.

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014.

Diarra B, Goita D, Tounkara S, Sanogo M, Baya B, Togo AC, Maiga M, Sarro YS, Kone A, Kone B, M'Baye O, Coulibaly N, Kassambara H, Cisse A, Belson M, Polis MA, Otu J, Gehre F, Antonio M, Dao S, Siddiqui S, Murphy RL, de Jong BC, Diallo S.

BMC Infect Dis. 2016 Nov 28;16(1):714.

32.

Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.

Scherrer D, Rouzier R, Cardona M, Barrett PN, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01288-16. doi: 10.1128/AAC.01288-16. Print 2017 Jan.

33.

Perspectives for immunotherapy: which applications might achieve an HIV functional cure?

Vieillard V, Gharakhanian S, Lucar O, Katlama C, Launay O, Autran B, Ho Tsong Fang R, Crouzet J, Murphy RL, Debré P.

Oncotarget. 2016 Jun 21;7(25):38946-38958. doi: 10.18632/oncotarget.7793. Review.

34.

Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako, Mali.

Maiga M, Cohen K, Baya B, Srikrishna G, Siddiqui S, Sanogo M, Somboro AM, Diarra B, Diallo MH, Mazumdar V, Yoder C, Orsega S, Belson M, Kassambara H, Goita D, Murphy RL, Dao S, Polis M, Diallo S, Timmins GS, Dodd L, Earl AM, Bishai WR.

J Breath Res. 2016 Aug 17;10(3):036012. doi: 10.1088/1752-7155/10/3/036012.

35.

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ.

PLoS One. 2016 Aug 8;11(8):e0160341. doi: 10.1371/journal.pone.0160341. eCollection 2016.

36.

Molecular identification of Mycobacterium bovis from cattle and human host in Mali: expanded genetic diversity.

Diallo M, Diarra B, Sanogo M, Togo AC, Somboro AM, Diallo MH, Traoré B, Maiga M, Koné Y, Tounkara K, Sarro YD, Baya B, Goita D, Kassambara H, Dembélé BP, Siddiqui S, Murphy RL, Dao S, Diallo S, Tounkara A, Niang M.

BMC Vet Res. 2016 Jul 20;12(1):145. doi: 10.1186/s12917-016-0768-7.

37.

Is there any relationship between hearing threshold levels and CD4 cell count of human immunodeficiency virus infected adults?

Fasunla AJ, Ijitola JO, Akpa OM, Nwaorgu OGB, Taiwo B, Olaleye DO, Murphy RL, Adewole IF, Akinyinka OO.

Afr J Med Med Sci. 2016 May;45(1):51-60.

PMID:
28686827
38.

Cervical cancer survival in a resource-limited setting-North Central Nigeria.

Musa J, Nankat J, Achenbach CJ, Shambe IH, Taiwo BO, Mandong B, Daru PH, Murphy RL, Sagay AS.

Infect Agent Cancer. 2016 Mar 24;11:15. doi: 10.1186/s13027-016-0062-0. eCollection 2016.

39.

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.

Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, Murphy RL, Calvez V, Costagliola D, Autran B; EraMune-01 study team.

AIDS. 2016 Jan;30(2):221-30. doi: 10.1097/QAD.0000000000000894.

PMID:
26684819
40.

A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection.

Wilkinson J, Ewart G, Luscombe C, McBride K, Ratanasuwan W, Miller M, Murphy RL.

J Antimicrob Chemother. 2016 Mar;71(3):731-8. doi: 10.1093/jac/dkv389. Epub 2015 Nov 29.

PMID:
26620101
41.

Clinical Research and the Training of Host Country Investigators: Essential Health Priorities for Disease-Endemic Regions.

Koita OA, Murphy RL, Fongoro S, Diallo B, Doumbia SO, Traoré M, Krogstad DJ.

Am J Trop Med Hyg. 2016 Feb;94(2):253-257. doi: 10.4269/ajtmh.15-0366. Epub 2015 Nov 23.

42.

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.

Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen Tchetgen EJ, Agbaji OO, Onwujekwe DI, Gashau W, Nkado R, Okonkwo P, Murphy RL, Kanki PJ; Harvard/APIN PEPFAR Team.

Clin Infect Dis. 2016 Feb 15;62(4):512-8. doi: 10.1093/cid/civ928. Epub 2015 Nov 10.

43.

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

Achenbach CJ, Assoumou L, Deeks SG, Wilkin TJ, Berzins B, Casazza JP, Lambert-Niclot S, Koup RA, Costagliola D, Calvez V, Katlama C, Autran B, Murphy RL; EraMune 02 study team.

Lancet HIV. 2015 Mar;2(3):e82-91. doi: 10.1016/S2352-3018(15)00026-0. Epub 2015 Feb 17.

44.

Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.

Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK.

Antimicrob Agents Chemother. 2015 Dec;59(12):7852-6. doi: 10.1128/AAC.01153-15. Epub 2015 Sep 21.

45.

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.

Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Brodell EL, Kelesidis T, McComsey GA, Dube MP, Murphy RL, Currier JS.

AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. Erratum in: AIDS. 2016 Jan;30(2):337.

46.

Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA.

J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5.

47.

High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology.

Musa J, Achenbach C, Taiwo B, Berzins B, Silas O, Daru PH, Agbaji O, Imade G, Sagay AS, Idoko JA, Kanki PJ, Murphy RL.

Infect Agent Cancer. 2014 Nov 3;9(1):36. doi: 10.1186/1750-9378-9-36. eCollection 2014.

48.

Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria--Implications for Care.

Kuti MA, Adesina OA, Awolude OA, Ogunbosi BO, Fayemiwo SA, Akinyemi JO, Adetunji AA, Irabor AE, Odaibo GN, Prosper O, Taiwo BO, Olaleye D, Murphy RL, Kanki P, Adewole IF.

J Int Assoc Provid AIDS Care. 2015 Jul-Aug;14(4):355-9. doi: 10.1177/2325957414555227. Epub 2014 Oct 20.

PMID:
25331224
49.

Comparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell counts.

Fasunla AJ, Ogunbosi BO, Odaibo GN, Nwaorgu OG, Taiwo B, Olaleye DO, Osinusi K, Murphy RL, Adewole IF, Akinyinka OO.

AIDS. 2014 Sep 24;28(15):2223-30. doi: 10.1097/QAD.0000000000000393.

50.

Sorghum phytochrome B inhibits flowering in long days by activating expression of SbPRR37 and SbGHD7, repressors of SbEHD1, SbCN8 and SbCN12.

Yang S, Murphy RL, Morishige DT, Klein PE, Rooney WL, Mullet JE.

PLoS One. 2014 Aug 14;9(8):e105352. doi: 10.1371/journal.pone.0105352. eCollection 2014.

Supplemental Content

Loading ...
Support Center